Pre-made Nemolizumab benchmark antibody ( Whole mAb, anti-IL31RA/IL31R therapeutic antibody, Anti-CRL/CRL3/GLM-R/GLMR/GPL/IL-31RA/PLCA2/PRO21384/hGLM-R/zcytoR17 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Nemolizumab biosimilar, Whole mAb, Anti-IL31RA/IL31R Antibody: Anti-CRL/CRL3/GLM-R/GLMR/GPL/IL-31RA/PLCA2/PRO21384/hGLM-R/zcytoR17 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Nemolizumab is an experimental drug for the treatment of itching in people with atopic dermatitis. It is a monoclonal antibody that blocks the interleukin-31 receptor A. Results of a Phase II clinical trial were published in March 2017.
| Products Name (INN Index) | Pre-Made Nemolizumab biosimilar, Whole mAb, Anti-IL31RA/IL31R Antibody: Anti-CRL/CRL3/GLM-R/GLMR/GPL/IL-31RA/PLCA2/PRO21384/hGLM-R/zcytoR17 therapeutic antibody |
|---|---|
| INN Name | Nemolizumab |
| Target | IL31RA |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG2 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2014 |
| Year Recommended | 2015 |
| Companies | Chugai Pharmaceutical,Galderma,Maruho |
| Conditions Approved | NA |
| Conditions Active | Atopic dermatitis,Prurigo nodularis,Pruritus |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | IL31RA |
| Package |
